Tenaya Therapeutics Enters Material Definitive Agreement
Ticker: TNYA · Form: 8-K · Filed: Feb 8, 2024
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
**Tenaya Therapeutics just signed a big deal, watch for details.**
AI Summary
Tenaya Therapeutics, Inc. filed an 8-K on February 8, 2024, reporting an "Entry into a Material Definitive Agreement" on February 7, 2024. This filing indicates that the company has entered into a significant contract or partnership, which could impact its future operations and financial performance. For investors, this matters because material agreements often signal new revenue streams, strategic collaborations, or significant operational changes that could affect the stock's valuation.
Why It Matters
This filing signals a new, significant business arrangement for Tenaya Therapeutics, which could lead to new opportunities or obligations that impact its financial health and stock price.
Risk Assessment
Risk Level: medium — The filing indicates a material agreement but provides no details, creating uncertainty about its nature and potential impact, which could be positive or negative.
Analyst Insight
A smart investor would monitor Tenaya Therapeutics (TNYA) for follow-up announcements or filings that disclose the specifics of this material definitive agreement, as its terms will dictate the actual impact on the company.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — registrant
- February 7, 2024 (date) — date of earliest event reported
- February 8, 2024 (date) — filing date
- 001-40656 (other) — Commission File Number
- TNYA (other) — Trading Symbol
Forward-Looking Statements
- Tenaya Therapeutics will provide more details about the material definitive agreement in a subsequent filing or press release. (Tenaya Therapeutics, Inc.) — high confidence, target: 2024-03-01
FAQ
What was the specific event reported in this 8-K filing by Tenaya Therapeutics, Inc.?
The specific event reported was the "Entry into a Material Definitive Agreement" on February 7, 2024, as stated under ITEM INFORMATION.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 7, 2024, as indicated by "Date of Report (Date of earliest event reported): February 7, 2024."
What is the trading symbol for Tenaya Therapeutics, Inc.?
The trading symbol for Tenaya Therapeutics, Inc. is TNYA, as listed under "Trading Symbol(s)" in the filing.
On which exchange is Tenaya Therapeutics, Inc.'s common stock registered?
Tenaya Therapeutics, Inc.'s common stock is registered on The Nasdaq Global Select Market, as stated under "Name of exchange on which registered."
What is the business address of Tenaya Therapeutics, Inc.?
The business address of Tenaya Therapeutics, Inc. is 171 Oyster Point Boulevard, Suite 500, South San Francisco, CA 94080, as provided in the filing.
Filing Stats: 1,557 words · 6 min read · ~5 pages · Grade level 12 · Accepted 2024-02-08 08:15:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TNYA The Nasdaq
- $4.50 — 0001 per share, at an offering price of $4.50 per share and pre-funded warrants (the
- $4.499 — 's common stock at an offering price of $4.499 per underlying share. Under the terms o
- $4.23 — e Shares from the Company at a price of $4.23 per share and the Pre-Funded Warrants a
- $50.0 million — penses are expected to be approximately $50.0 million. The Offering is expected to close on F
- $0.001 — rice per share of common stock equal to $0.001 per share. The exercise price and the n
Filing Documents
- d761271d8k.htm (8-K) — 36KB
- d761271dex11.htm (EX-1.1) — 176KB
- d761271dex41.htm (EX-4.1) — 56KB
- d761271dex51.htm (EX-5.1) — 11KB
- d761271dex991.htm (EX-99.1) — 8KB
- g761271dsp001a.jpg (GRAPHIC) — 4KB
- g761271dsp001b.jpg (GRAPHIC) — 2KB
- 0001193125-24-027611.txt ( ) — 497KB
- tnya-20240207.xsd (EX-101.SCH) — 3KB
- tnya-20240207_lab.xml (EX-101.LAB) — 18KB
- tnya-20240207_pre.xml (EX-101.PRE) — 11KB
- d761271d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Certain of the statements made in this report are forward looking, such as those, among others, relating to the Company's expectations regarding the timing and completion of the Offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the Offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the Offering. More information about the risks and uncertainties faced by the Company is contained under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 8, 2023. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. 1.1 Underwriting Agreement between the Company, Leerink Partners LLC and Cowen and Company, LLC, dated as of February 7, 2024. 4.1 Form of Pre-Funded Warrant 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation. 23.1 Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included with the opinion filed as Exhibit 5.1). 99.1 Press Release dated February 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENAYA THERAPEUTICS, INC. By: /s/ Leone D. Patterson, M.B.A. Leone D. Patterson, M.B.A. Chief Financial and Business Officer Date: February 8, 2024